Clinical trials
Relapsed or Refractory Plasma Cell Neoplasms clinical trials
Below are recruiting relapsed or refractory plasma cell neoplasms clinical trials, each written for real people, not researchers. We’re tracking 1,654 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06791681RecruitingEarly Phase 1
ESO-T01 for returning or hard-to-treat multiple myeloma
This trial tests a new treatment called ESO-T01 for people with multiple myeloma that has come back or is not responding to at least two prior therapies. It aims to see if this therapy is safe and can help control the disease.
Wuhan, HubeiAges 18 years+ - NCT07382739RecruitingPhase 2
Radiation and immunotherapy for advanced multiple myeloma
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
Houston, TexasAges Any age - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25 - NCT07312188RecruitingPhase 2
F182112 for relapsed or refractory multiple myeloma
This trial tests a new drug, F182112, for people whose multiple myeloma came back or didn't respond to prior treatments that included lenalidomide and a proteasome inhibitor. It may help if your disease has active signs like high protein levels.
TianjinAges 18 years+ - NCT06484829RecruitingPhase 1/Phase 2
New drug combo for relapsed or refractory multiple myeloma
This trial tests a new drug, purinostat mesylate, combined with pomalidomide (a chemotherapy pill) and a low-dose steroid (dexamethasone) for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if this combination can help control the cancer with manageable side effects.
Chengdu, SichuanAges 18–75 - NCT07228624RecruitingPhase 2
Ruxolitinib before, during, and after transplant for myelofibrosis
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
Seattle, WashingtonAges 18–75 - NCT07138209RecruitingPhase 3
Comparing QLS32015 to standard treatments for multiple myeloma
This trial tests a new drug, QLS32015, against two common treatments for multiple myeloma that has come back or not responded to therapy. It may be an option for people who have already tried several treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07137637RecruitingPhase 1
HPB-092 for relapsed or refractory AML
This trial tests a new drug, HPB-092, in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if it can help when other treatments have not worked.
TianjinAges 18 years+ - NCT07144254RecruitingPhase 1
Tegavivint and gemcitabine for relapsed osteosarcoma
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
Atlanta, GeorgiaAges 1–30 - NCT07121322RecruitingPhase 2
Dornase Alfa and Cisplatin for resistant germ cell cancer
This trial tests a combination of two drugs, dornase alfa and cisplatin, for men with germ cell cancer that has not responded to standard treatments or has come back. The goal is to see if this new combination can shrink tumors or stop them from growing.
BratislavaAges 18 years+ - NCT07116616RecruitingPhase 1/Phase 2
mRNA vaccine for relapsed or refractory multiple myeloma
This trial tests an experimental mRNA therapy called mRNA-2808 for people with multiple myeloma that has returned or stopped responding to prior treatments. It aims to see if it can help control the disease.
Birmingham, AlabamaAges 18 years+ - NCT07096778RecruitingPhase 2
Combination therapy for returning multiple myeloma
This trial tests a new drug called inobrodib combined with two standard treatments (pomalidomide and dexamethasone) for people whose multiple myeloma has come back or did not respond. The goal is to see if this combination can help control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT05759793RecruitingPhase 1
CAR T trial for relapsed myeloma targeting GPRC5D
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
ShanghaiAges 18–75 - NCT07075510RecruitingPhase 1/Phase 2
Comparing Daratumumab injection in thigh vs. abdomen for plasma cell disorders
This trial is for people with multiple myeloma or AL amyloidosis who are about to start treatment with a drug called daratumumab. It compares two places to inject the medicine (thigh vs. abdomen) to see which works better and is more comfortable.
Baltimore, MarylandAges 18 years+ - NCT07027748RecruitingPhase 1
Testing a longer treatment of three drugs for neuroblastoma
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
Boston, MassachusettsAges 1–30 - NCT07032714RecruitingPhase 1
Mezigdomide and talquetamab for relapsed multiple myeloma
This trial tests a combination of two drugs, mezigdomide (a pill) and talquetamab (an injection), for people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see if this combination can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT07020533RecruitingPhase 1
CMV vaccine for stem cell transplant recipients
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT05219721RecruitingPhase 1
CAR T-cell study for relapsed multiple myeloma with GPRC5D
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
Wuhan, HubeiAges 18–75 - NCT06952478RecruitingPhase 3
Comparing a new injectable multiple myeloma drug to Darzalex Faspro
This trial compares a new injectable medicine (CT-P44) to an approved one (Darzalex Faspro), both given with lenalidomide and dexamethasone, for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if the new option works just as well.
Taipei, Beitou DistrictAges 18 years+ - NCT06846606RecruitingPhase 1
Study of AUTX-703 for advanced blood cancers
This trial tests an experimental drug, AUTX-703, for people with certain blood cancers (AML or MDS) that have returned or not improved after other treatments. The goal is to see if the drug is safe and helps control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06832865RecruitingPhase 2
Combination immunotherapy for relapsed multiple myeloma
This trial tests two drugs, elranatamab and isatuximab, given together to people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if the combination can shrink or control the cancer where other therapies have not worked well.
Boston, MassachusettsAges 18 years+ - NCT06812104RecruitingPhase 1
A trial of KK2845 for certain blood cancers
This trial is testing a new drug, KK2845, for people with certain blood cancers that have come back or not responded to treatment. It focuses on acute myeloid leukemia (AML) and other blood cancers.
Kamogawa, ChibaAges 18 years+ - NCT06718634RecruitingPhase 1
Study of BL-M08D1 for returning blood cancers
This trial tests a new drug called BL-M08D1 for people with lymphoma or other blood cancers that came back or didn't respond to standard treatments. It aims to see if the drug can help when other options are no longer working.
Harbin, HeilongjiangAges 18–75
Hear when a new Relapsed or Refractory Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory plasma cell neoplasms?
- Yes. Clin2 currently lists 1,654 recruiting relapsed or refractory plasma cell neoplasms studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory plasma cell neoplasms trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory plasma cell neoplasms trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
- Refractory Plasma Cell Myeloma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Multiple Myeloma and Malignant Plasma Cell Neoplasms
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.